Medical Condition News

RSS

CaPre drug candidate shows promising result on CRP level reduction

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre on C-reactive protein (CRP) levels, a biomarker of CardioVascular Disease risk (CVD) and associated with diabetes and obesity.

3 Sep 2010

Cerebral palsy risk rises in post term babies: Study

Babies born past their due dates – at 42 weeks or later, are at increased risk for cerebral palsy compared to those born at 40 weeks, according to new research. That said, the actual risk of cerebral palsy remains low. According to the CDC one in 303 children have some type of cerebral palsy. Common symptoms may include movement problems, muscle stiffness, poor muscle tone, and spasticity. The symptoms are thought to result from injury to the brain as a fetus or early in infancy.

2 Sep 2010

Biologists find daily exercise as a heritable trait

Biologists at the University of California, Riverside have found that voluntary activity, such as daily exercise, is a highly heritable trait that can be passed down genetically to successive generations.

2 Sep 2010

Researchers discover protein that stimulates production of beta-amyloid

Researchers at the Fisher Center for Alzheimer's Disease Research laboratory today published "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease" in Nature online. Drs. Gen He (lead author) and Paul Greengard have discovered a protein that stimulates the production of beta-amyloid, and therefore represents a major new advance in Alzheimer's disease research.

2 Sep 2010

Short sleep duration increases risk of psychological distress

Young adults who get fewer than eight hours of sleep per night have greater risks of psychological distress, a combination of high levels of depressive and anxious symptoms, according to a study in the Sept. 1 issue of the journal SLEEP.

2 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Achievement of sufficient night sleep needed in obesity prevention and weight-management programs

A study in the Sept. 1 issue of the journal Sleep shows that teens who slept less than eight hours per weeknight ate higher proportions of fatty foods and snacks than adolescents who slept eight hours or more. The results suggest that short sleep duration may increase obesity risk by causing small changes in eating patterns that cumulatively alter energy balance, especially in girls.

2 Sep 2010

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology, analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay.

2 Sep 2010

Parents tend to underreport their children's weight, find researchers

As the U.S. launches its first-ever National Childhood Obesity Awareness Month today, scientists say the problem may be even more widespread than was thought. Researchers have found that parents tend to underreport their children's weight. Estimates of obesity and body mass index based on parent-supplied data may miss one in five obese children.

2 Sep 2010

Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20

Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.

2 Sep 2010

Mindfulness training increases well-being in adolescents, reports new study

'Mindfulness', the process of learning to become more aware of our ongoing experiences, increases well-being in adolescent boys, a new study reports. Researchers from the University of Cambridge analyzed 155 boys from two independent UK schools, Tonbridge and Hampton, before and after a four-week crash course in mindfulness. After the trial period, the 14 and 15 year-old boys were found to have increased well-being, defined as the combination of feeling good (including positive emotions such as happiness, contentment, interest and affection) and functioning well.

2 Sep 2010

Benefit of delaying cognitive decline comes at the cost of more rapid dementia progression

New research shows that mentally stimulating activities such as crossword puzzles, reading and listening to the radio may, at first, slow the decline of thinking skills but speed up dementia later in old age. The research is published in the September 1, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Sep 2010

Gene mutations that express LRRK2 linked to increased risk of Parkinson's disease: Researchers

A significant number of Parkinson's disease patients have a mutation of the enzyme Leucine-Rich Repeat Protein Kinase 2 (LRRK2, also known as dardarin). However, little is understood about how it is regulated or functions. In a new paper in the Signal Knowledge Environment of the Biochemical Journal, Dario Alessi and colleagues from the University of Dundee demonstrate that a family of proteins, the 14-3-3 proteins, interact with LRRK2.

2 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

Researchers dispute study findings that show greater incidence of surgery for children with CD

A new multi-center study of 854 children with Crohn's disease shows a 5-year cumulative risk of bowel surgery is significantly lower than reported in recent studies. The findings of the study, led by Hasbro Children's Hospital, also indicate that children diagnosed between ages 13 and 16 had an increased risk of bowel surgery, and that a common treatment that begins at diagnosis, immunomodulator therapy, did not alter the risk of surgery.

2 Sep 2010

Agent Orange cases expanded; Added costs raise fiscal concerns

Hundreds of thousands of Vietnam War veterans are receiving disability compensation for diseases normally associated with aging - not combat - because of the possibility of a link Agent Orange exposure. The diseases in question range from diabetes, for which 270,000 veterans receive Agent Orange-related checks, to erectile dysfunction.

2 Sep 2010

Saint Barnabas Medical Center installs ZOLL's AutoPulse Non-Invasive Cardiac Support Pump

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that Saint Barnabas Medical Center, one of the largest non-profit, non-sectarian hospitals in New Jersey, has installed the AutoPulse® Non-Invasive Cardiac Support Pump for resuscitative capabilities in the hospital's emergency department.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.

2 Sep 2010

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment.

2 Sep 2010

Medical Condition News

CaPre drug candidate shows promising result on CRP level reduction

Cerebral palsy risk rises in post term babies: Study

Biologists find daily exercise as a heritable trait

Researchers discover protein that stimulates production of beta-amyloid

Short sleep duration increases risk of psychological distress

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Achievement of sufficient night sleep needed in obesity prevention and weight-management programs

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Parents tend to underreport their children's weight, find researchers

Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20

Mindfulness training increases well-being in adolescents, reports new study

Benefit of delaying cognitive decline comes at the cost of more rapid dementia progression

Gene mutations that express LRRK2 linked to increased risk of Parkinson's disease: Researchers

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Researchers dispute study findings that show greater incidence of surgery for children with CD

Agent Orange cases expanded; Added costs raise fiscal concerns

Saint Barnabas Medical Center installs ZOLL's AutoPulse Non-Invasive Cardiac Support Pump

XARELTO achieves net clinical benefit in treatment of patients with DVT

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News